DaVita (NYSE:DVA) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?
DaVita (NYSE:DVA) shares have moved above their 200-day moving average, signaling bullish momentum. The company recently reported strong earnings, beating analyst expectations and raising its FY2026 guidance. While MarketBeat's consensus rating is "Hold," some analysts, like UBS and Zacks, have upgraded their ratings and increased price targets.
ANGO shares rise in pre-market after surpassing Q3 earnings estimates, though gross margin declines
AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of $0.07 for Q3 fiscal 2026, exceeding analyst estimates, and saw an 8.9% increase in revenue to $78.4 million. The growth was driven by strong sales in its Med Tech segment, particularly Auryon, mechanical thrombectomy products, and NanoKnife. Despite these positive results and an updated fiscal 2026 guidance with increased net sales projections, the company experienced a decline in pro forma gross margin and continues to report adjusted operating losses.
DaVita Inc. stock outperforms competitors on strong trading day
Shares of DaVita Inc. (DVA) rose 3.12% to $150.12 on Monday, outperforming its competitors and the broader market. This gain snapped a two-day losing streak for the stock, coinciding with a strong trading session for the S&P 500 Index and the Dow Jones Industrial Average.
Day in the Life: Ansel, DaVita Home Hemodialysis Registered Nurse
The article highlights Ansel, a DaVita Home Hemodialysis Registered Nurse, who joined the company as a DaVita Global Nurse from the Philippines. He was drawn to DaVita's culture, benefits, and opportunities for professional and personal growth. The piece also provides an overview of DaVita Inc., a healthcare provider specializing in kidney care, detailing its global operations, patient reach, and commitment to improving quality of life for patients.
DaVita's "Move It With Purpose" Sets Record Participation in Support of Global Health
DaVita's third annual "Move It With Purpose" (MIWP) event achieved record participation, with over 8,300 individuals logging 550,000 miles of activity across nearly 150 events. This initiative raised more than $750,000 for Bridge of Life, a nonprofit founded by DaVita, to support chronic disease prevention and treatment globally. Since 2007, DaVita has raised over $15 million for Bridge of Life, helping nearly 150,000 individuals in 34 countries.
Day in the Life: Cristina, DaVita PD Registered Nurse
The article highlights Cristina, a DaVita PD Registered Nurse, and her career transition from in-center nursing to peritoneal dialysis (PD) to empower patients in managing their care. It also provides an overview of DaVita Inc., a healthcare provider specializing in kidney care globally, detailing their patient reach and commitment to improving care quality.
Day in the Life: Jena, DaVita Social Worker
Jena, a social worker at DaVita, emphasizes that her role extends beyond traditional desk-based therapy. She focuses on directly engaging with patients on the clinic floor to understand their needs and make their dialysis experience easier. DaVita (NYSE: DVA) is a healthcare provider dedicated to transforming care delivery and improving the quality of life for global patients, especially in kidney care.
DaVita (NYSE:DVA) - Stock Analysis
This report provides a comprehensive analysis of DaVita (NYSE:DVA), a kidney dialysis service provider, highlighting its current stock performance, valuation, future growth prospects, and financial health. The company is trading below its estimated fair value, with earnings projected to grow by 5.64% annually. Key narratives discuss the impact of policy shifts, operational recovery, international expansion, and integrated kidney care on its outlook and margins.
DaVita Entities’ Drug Purchases Exempt From Louisiana Sales Tax
A Louisiana court of appeals has ruled that five Jefferson Parish dialysis clinics, operated by DaVita, are exempt from paying sales tax on prescription drug purchases from wholesalers. This exemption applies because the drugs were administered to Medicare patients. The ruling specifically concerns DVA Healthcare Renal Care Inc. and four other clinics, which had previously remitted monthly sales tax payments on these purchases.
DaVita Inc. stock: Steady earnings beat amid market dips—what's next?
DaVita Inc. continues to demonstrate operational strength with consistent earnings beats, positioning itself as a stable healthcare investment, particularly in North America. Despite recent stock dips, the company's dominance in kidney care, predictable revenue streams, and strategic moves like integrated care models and home dialysis expansion suggest long-term growth potential. Investors should weigh these strengths against risks such as government reimbursement changes, labor shortages, and regulatory scrutiny.
DaVita Inc. stock: Steady earnings beat amid market dips—what's next?
DaVita Inc. continues to show strong earnings, beating expectations in Q4 2025 and Q2 2025, despite a recent 3.17% dip in share price. As a dominant player in U.S. kidney care, with a predictable revenue model tied to Medicare and commercial insurance, the company offers stability for North American investors. While analysts are balanced in their views and risks like government reimbursement cuts and labor shortages exist, DaVita's strategic moves into digital health and home dialysis, coupled with increasing demand for kidney care, suggest potential for future growth.
DaVita Inc Stock: Leading Dialysis Provider Faces Evolving Healthcare Landscape in 2026
DaVita Inc, a major player in U.S. dialysis services, continues to operate within a dynamic healthcare landscape characterized by regulatory pressures and a focus on operational efficiencies. The company, with a market capitalization of approximately $10 billion, provides essential kidney care and maintains a strong financial standing, supported by consistent profitability and strategic investments in home dialysis and integrated care models. Despite risks such as reimbursement rate cuts and labor shortages, DaVita offers North American investors defensive exposure to healthcare essentials, driven by an aging population and technological advancements in renal care.
Fresenius Medical Care stock: Dialysis giant's steady edge in a shaky market
Fresenius Medical Care, the world's largest dialysis provider, offers investors a stable healthcare play with its dominant presence in North America and recurring revenue stream from essential treatments for chronic kidney disease. The company's vertically integrated model, strong financial performance, and strategic focus on home dialysis position it for continued demand despite market volatility. Investors can consider FMC for defensive portfolios, monitoring U.S. reimbursement policies and competition.
DaVita Inc. stock underperforms Thursday when compared to competitors
DaVita Inc. (DVA) stock underperformed on Thursday compared to its competitors, closing at $121.75 after a 0.25% gain. Despite the daily gain, the stock lagged behind the S&P 500 and its peers like HCA Healthcare and Universal Health Services.
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
Shares of several pharmaceutical and healthcare companies, including AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie, declined following reports that the U.S. may impose up to 100% tariffs on imported branded and patented drugs. This potential tariff move targets pharmaceutical companies that have not negotiated lower drug prices in the U.S., causing a significant sell-off in the sector. Novavax, in particular, saw its shares drop, although the market's reaction suggests the news is meaningful but not fundamentally altering its business perception, with the stock still up for the year despite previous volatility.
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
Shares of several pharmaceutical and healthcare companies, including AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie, dropped significantly after reports suggested the U.S. might impose 100% tariffs on imported branded and patented drugs. This potential policy aims to target companies that haven't negotiated lower drug prices in the U.S., causing a sector-wide sell-off. The article highlights Novavax's volatility and its prior drop due to U.S.-Iran conflict concerns.
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
Shares of several healthcare and pharmaceutical companies, including AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie, plummeted following reports that the U.S. might impose up to 100% tariffs on imported branded and patented drugs. This potential move, targeting companies not negotiating lower drug prices, caused a significant sell-off in the sector. Novavax's shares were particularly volatile, though the market's reaction suggests the news is meaningful but not fundamentally business-altering.
DaVita Inc. stock underperforms Thursday when compared to competitors
Shares of DaVita Inc. (DVA) fell 3.17% to $145.58 on Thursday, extending its losing streak to a second consecutive day. The decline occurred during a mixed trading session where the S&P 500 Index rose 0.11% and the Dow Jones Industrial Average fell 0.13%. The stock's performance lagged behind its competitors.
Fresenius Medical Care Stock: Key Factors Shaping Investor Outlook for North American Markets
Fresenius Medical Care, a global leader in dialysis products and services, plays a significant role in the North American chronic kidney disease market. The company's stable business model, focus on innovation, and strong market position make it attractive to investors. Key factors like Medicare policies, competitive landscape, and ongoing R&D in digital health affect its performance and future growth.
Ambulatory Healthcare Service Market Size 2026 Emerging Demands, Share, Trends, Futuristic Opportunity, Share and Forecast To 2033 | Tenet Healthcare Corporation, HCA Healthcare Inc., Universal Health Services Inc., Encompass Health Corporation
The global ambulatory healthcare service market is projected to grow from USD 970.77 billion in 2026 to USD 1,431.01 billion by 2033, demonstrating a compound annual growth rate (CAGR) of 5.7%. This report from Coherent Market Insights offers a detailed analysis of market segmentation, competitive landscape, regional trends, and strategic insights for decision-makers. Key companies like Tenet Healthcare Corporation, HCA Healthcare Inc., and Universal Health Services Inc. are highlighted among the top players.
DaVita Inc. stock underperforms Wednesday when compared to competitors
Shares of DaVita Inc. (DVA) fell 2.18% on Wednesday, closing at $150.34, despite a generally positive trading session for the broader stock market. The S&P 500 Index and Dow Jones Industrial Average both saw gains. DaVita Inc. stock is currently 5.70% below its 52-week high.
Chemed schedules April 24 call after Q1 results on April 23
Chemed Corporation (NYSE: CHE) announced that it will release its first-quarter 2026 financial results on April 23, 2026, after the NYSE close. The company will host a conference call and webcast on April 24, 2026, at 10:00 a.m. ET to discuss the results and provide a business update. Investors can access the webcast or register for a teleconference call, with a replay available approximately two hours after the event.
Assenagon Asset Management Trims DaVita Stake
Assenagon Asset Management S.A. has reduced its stake in DaVita Inc. by 37.7% during the fourth quarter, selling 25,780 shares and now owning 42,628 shares. This divestment by a major institutional investor could signal concerns about DaVita's future performance or the broader dialysis industry. The article suggests monitoring whether other large investors follow suit.
Assenagon Asset Management S.A. Trims Holdings in DaVita Inc. $DVA
Assenagon Asset Management S.A. significantly reduced its stake in DaVita Inc. by 37.7% in the fourth quarter, selling 25,780 shares and retaining 42,628 shares valued at $4.84 million. Despite this, institutional investors collectively own over 90% of the company's stock. DaVita exceeded Q4 expectations with $3.40 EPS and $3.62 billion in revenue, leading to an average analyst rating of "Hold" and a target price of $155.80.
DaVita stock dips 1.49% as company promotes home dialysis benefits
DaVita (DVA) stock experienced a 1.49% dip despite the company highlighting the health and lifestyle advantages of home dialysis. The stock, currently at $154.43, shows a bullish technical structure, trading above major moving averages and near its 52-week high, although some oscillators suggest overbought conditions. Analysts project a trading range of $154.35 to $159.64 for the coming week, with a sustained breakout above $157.18 indicating further potential gains.
Rockwell Medical Earnings Call Balances Progress and Risk
Rockwell Medical's Q4 earnings call revealed mixed results, highlighting operational improvements and stronger cash generation, but also significant revenue declines. The company achieved positive adjusted EBITDA and margin expansion, strengthened its balance sheet, and broadened its customer base. However, a wider net loss and heavy dependence on large customers indicate that a full recovery is still in progress, with future growth contingent on successful contract negotiations.
Wedge Capital Management L L P NC Purchases 45,998 Shares of DaVita Inc. $DVA
Wedge Capital Management L L P NC has increased its stake in DaVita Inc. by 18.3%, acquiring 45,998 additional shares, bringing its total holdings to 296,916 shares valued at approximately $33.7 million. DaVita recently exceeded quarterly earnings expectations with $3.40 EPS and $3.62 billion in revenue, also providing strong FY2026 guidance. Analysts currently maintain a consensus "Hold" rating with an average price target of $155.80, though some firms like UBS have raised their targets.
SG Americas Securities LLC Increases Stake in DaVita Inc. $DVA
SG Americas Securities LLC significantly increased its stake in DaVita Inc. by 271.7% in Q4 2025, now holding 166,684 shares valued at $18.94 million. DaVita reported strong Q4 results, beating earnings expectations with $3.40 EPS and 9.9% revenue growth, and provided optimistic FY2026 guidance. While institutional ownership is high, analyst ratings are mixed, with a consensus "Hold" but an average target price of $155.80.
Should Value Investors Buy DaVita (DVA) Stock?
DaVita (DVA) stock is highlighted as a potential value investment due to its strong Zacks Rank #2 (Buy) and a Value grade of 'A'. The article points to attractive valuation metrics such as a P/E ratio of 10.65, a PEG ratio of 0.83, and a P/S ratio of 0.77, all comparing favorably to its industry averages. These indicators suggest that DaVita may be undervalued, making it an appealing option for value investors.
Fresenius Medical Care Stock: Key Business Drivers and Investment Considerations for North American Investors
Fresenius Medical Care is a global leader in dialysis services and products, with a significant presence in North America, particularly the U.S. The company's business model, which integrates product manufacturing and service delivery through clinics, provides resilience and predictable revenue streams. North American investors find the stock relevant due to its dominant U.S. market share, exposure to an aging population, and strategic investments in value-based care and digital health, alongside stable financial performance and a consistent dividend policy.
DaVita Inc. stock outperforms competitors despite losses on the day
Despite a losing day for the overall stock market, DaVita Inc. (DVA) shares only fell 1.49% to $154.43 while the S&P 500 Index dropped 1.67% and the Dow Jones Industrial Average declined 1.73%. This performance signifies that DaVita Inc. outperformed its competitors even though its stock experienced a slight fall, breaking a four-day winning streak.
Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2025 Earnings Call Transcript
Rockwell Medical, Inc. (RMTI) held its Q4 2025 earnings call, reporting a miss on EPS expectations but achieving profitability on an adjusted EBITDA basis for the second consecutive year. The company highlighted strategic changes including diversifying its customer base, optimizing operations for efficiency, and expanding its product portfolio. RMTI projects positive adjusted EBITDA and operating cash flow for 2026, with long-term goals of over $100 million in annual net sales by 2029 and gross margins approaching 30%.
Vanguard disaggregates holdings; DVA shows 0 shares (DVA)
Vanguard has amended its Schedule 13G for DaVita Inc. (DVA), reporting 0 shares of Common Stock. This change is due to an internal realignment on January 12, 2026, where certain subsidiaries will now report beneficial ownership separately. The filing clarifies that Vanguard no longer beneficially owns these securities following the disaggregation, rather than indicating a sale.
Earnings call transcript: Rockwell Medical Q4 2025 beats EPS forecast
Rockwell Medical Inc. reported strong Q4 2025 results, beating EPS forecasts by 140% with $0.02 against an expected -$0.05, and revenue surpassing expectations at $18.3 million. Despite a premarket stock drop, the company highlighted operational improvements, gross margin expansion, and positive cash flow. Rockwell Medical outlined a strategy for sustainable growth, intending to diversify its product portfolio and achieve over $100 million in annual net sales by 2029 with improved gross margins.
Here's why you should add DaVita stock to your portfolio for now
This article suggests adding DaVita (DVA) stock to an investment portfolio.
DaVita Inc. stock faces scrutiny amid dialysis sector reimbursement pressures and Medicare policy shifts
DaVita Inc. (DVA), a leading U.S. dialysis provider, is facing scrutiny due to potential Medicare reimbursement rate cuts. These policy changes, particularly regarding end-stage renal disease treatments, could impact the company's profitability and growth, making it a critical stock for U.S. investors to monitor. Despite operational resilience and diversification efforts, DaVita's strong reliance on government payors and its market dominance mean any reimbursement compression could significantly affect its revenue and stock performance.
Flexibility of a Home Dialysis Nurse
The article highlights the flexibility offered to home dialysis nurses at DaVita, featuring Ansel, a Home Hemodialysis Registered Nurse, who discusses his flexible schedule. DaVita focuses on enabling teammates to balance career growth with personal well-being. The company, a leading kidney care provider, serves approximately 281,100 patients globally and emphasizes innovation and improved quality of life for its patients.
DaVita Inc. stock faces scrutiny amid dialysis sector reimbursement pressures and Medicare policy sh
DaVita Inc., a leading U.S. dialysis provider, faces scrutiny over reimbursement pressures from Medicare Advantage plans and evolving federal policies. Despite these challenges, the company demonstrates operational strength through its extensive network and a pivot towards higher-margin home dialysis. Investors are watching Q1 earnings for indications of patient retention and operational efficiency, considering the stock a defensive play in a volatile market due to its stable financial health and cash-generative model.
Nordea Investment Management AB Boosts Holdings in DaVita Inc. $DVA
Nordea Investment Management AB significantly increased its stake in DaVita Inc. (NYSE:DVA) by 18% in Q4, acquiring an additional 51,607 shares, bringing its total holding to 338,192 shares valued at approximately $38.3 million. This increase contributes to the overall institutional ownership of DaVita, which stands at about 90.12%. DaVita recently surpassed earnings expectations with an EPS of $3.40 and revenue of $3.62 billion, and has provided strong FY2026 EPS guidance, amidst a "Hold" consensus rating from analysts with an average price target of $155.80.
DaVita Inc. stock outperforms competitors on strong trading day
Shares of DaVita Inc. (DVA) rose 1.94% to $152.21 on Monday, outperforming the broader market which also saw gains with the S&P 500 Index and Dow Jones Industrial Average rising. The stock closed 4.52% below its 52-week high.
Alexandria Real Estate Encounters Twofold Liquidity Challenge Amidst Index Adjustment and Socorro Departure
Alexandria Real Estate Equities (ARE) is facing a dual liquidity challenge due to its removal from the FTSE All-World Index, effective March 21, 2026, and the complete divestment of holdings by Socorro Asset Management LP. While the index removal is a liquidity event not impacting fundamentals, and Socorro's exit adds selling pressure, the company's long-term struggles are rooted in operational issues like declining occupancy rates and asset impairments, exacerbated by challenging capital market conditions. Investors are advised to focus on ARE's operational performance, capital allocation, and ability to stabilize net operating income rather than temporary index-driven volatility.
Fresenius Medical Care stock faces transition year pressures amid parent group insider confidence
Fresenius Medical Care (FMC) is facing a challenging "transition year" in 2026 due to U.S. reimbursement pressures, leading to a stock decline. However, a significant insider purchase by the CFO of parent company Fresenius SE, alongside robust group performance and deleveraging, suggests underlying confidence. This situation presents a potential entry point for DACH investors seeking undervalued healthcare exposure, balancing FMC's specific headwinds with broader group strength and demographic tailwinds in renal care.
Fresenius Medical Care stock faces headwinds from US competition and reimbursement pressures amid sector shifts
Fresenius Medical Care (ISIN: DE0005785802) is experiencing stock pressure due to intense competition from US rivals like DaVita and ongoing reimbursement challenges in the dialysis sector, especially in North America which accounts for over 60% of its revenue. This situation is impacting DAX-heavy portfolios for DACH investors, prompting reevaluation of healthcare allocations. Despite these headwinds, the company maintains financial resilience, stable European operations, and is focusing on strategic initiatives and cost discipline to navigate market shifts and regulatory concerns.
Fresenius Medical Care stock under pressure amid US reimbursement headwinds and sector challenges
Fresenius Medical Care (DE0005785802) is experiencing selling pressure on its Xetra-listed shares due to US reimbursement uncertainties and increased competition from rivals like DaVita. The company has declared 2026 a "transition year," characterized by operational adjustments, softer dynamics in North America, and ongoing issues with reimbursement rates. Despite these challenges, its robust European operations and strategic cost controls offer a stabilizing force and potential value for DACH investors, who are advised to monitor US policy developments closely.
Fresenius Medical Care stock faces headwinds from US competition and reimbursement pressures amid sector shifts
Fresenius Medical Care (DE0005785802) is experiencing stock pressure due to intensified competition from US rivals like DaVita and ongoing reimbursement challenges in dialysis services, particularly with its significant North American revenue exposure. Despite stable European operations providing some buffer and a solid balance sheet, rising US costs, regulatory changes, and competitive gains pose significant risks. The company continues to navigate these headwinds through strategic investments and cost discipline, though analyst consensus remains cautious.
How Investors Are Reacting To DaVita (DVA) CKCC Savings And Value-Based Kidney Care Momentum
DaVita (DVA) recently reported strong quarterly results, with revenue and adjusted EPS exceeding analyst expectations, driven by its Integrated Kidney Care business and over $200 million in shared savings from its CKCC value-based care programs. This success reinforces the credibility of its value-based care initiatives as a potential earnings contributor, even as the core dialysis business faces volume and reimbursement pressures. While the positive CKCC results are a catalyst, investors are advised to consider the ongoing risks of treatment volume fluctuations and reimbursement changes on future earnings, with varying analyst forecasts for long-term growth and fair value.
Fresenius Medical Care stock faces headwinds amid sector shifts and competitive pressures
Fresenius Medical Care (FME) stock is experiencing significant headwinds, trading lower on Xetra amidst intense competition from US peers like DaVita and broader sector shifts in dialysis services. The company faces challenges including rising costs, reimbursement pressures, and has underperformed compared to rivals with stronger revenue execution. DACH investors are closely monitoring FME's North American operations, its largest revenue source, as dynamics in the US dialysis market directly impact the company's performance and present risks for heavily weighted healthcare portfolios.
Truist Lowers PT on DaVita Inc. (DVA), Keeps a Hold Rating
Truist Financial has revised its price target for DaVita Inc. (DVA) downwards while maintaining a "Hold" rating on the stock. This adjustment reflects a moderated outlook for the company by the analyst firm.
Truist Lowers PT on DaVita Inc. (DVA), Keeps a Hold Rating
Truist Financial has lowered its price target for DaVita Inc. (DVA) while maintaining a "Hold" rating on the stock. This adjustment indicates a revised outlook on the company's future performance or valuation by the investment firm.
Outset Medical to detail in-house dialysis rollout and nurse impact at AONL2026
Outset Medical will present at AONL2026, where Brittni McGill and Melissa Alvillar will discuss the company's in-house dialysis initiative using Tablo Dialysis technology. The presentation will cover operational and clinical implications for nurses and patients, and the strategic reasons for bringing dialysis services in-house. This move reflects a broader trend towards insourced dialysis to improve efficiency and patient outcomes.
